Thank you for your interest in a GaBI Journal subscription.
GaBI Journal is an international journal publishing independent, high quality, authoritative and peer reviewed scientific articles concerning any aspect of the research into and development of cost-effective medicines, irrespective of their source. It includes expert analysis, review articles, briefings and updates on all aspects of comparative bioavailability, bioequivalence studies (traditional and biopharmaceutical), drug safety and risk management, drug production, analytical manufacturing methodology, drug/formulation development, biopharmaceutical and generics regulatory issues, healthcare policies and medicines policies, health economics, patient information, drug stereoisomerism including chirality, etc. Each issue publishes papers which are of direct relevance to healthcare professionals and practitioners and that meet the highest scientific standards.
We continuously strive to provide you with the most up-to-date information on research into and development of the science of generics and biosimilar medicines relevant to your profession.
To help us further develop GaBI, we would be grateful if you could recommend your colleagues and users at your institution or associates in your professional network to subscribe to GaBI Journal.
GaBI Journal is committed to its subscribers via sharing of professional and peer reviewed information supporting the development of cost-effective treatments.
Sign-up here to receive an email alert on the content of forthcoming issues.
GaBI’s mission – Building trust in cost-effective treatments. Support GaBI.
Click here to subscribe or submit your subscription via the online Subscription Form below.
Subscription Form
GaBI Journal is distributed free to selected healthcare professionals in clinical practice (physicians and pharmacists) and healthcare policies, pharmaceutical experts and scientists worldwide. Subscription is available to individuals, institutions, universities, hospitals, corporations and students.
Subscription rates cover four (4) issues of GaBI Journal per year. Single print copy = €180.
| SUBSCRIPTION RATES 2024 | ||
|---|---|---|
| Category | Europe | Non-Europe |
| Individual* | € 754 | € 764 |
| Hospital/University | € 1,383 | € 1,423 |
| Corporate** | € 2,915 | € 2,995 |
| Student* | € 629 | € 669 |
Subscription starts automatically with the next available issue after receipt of payment.
*Individuals, students and organisations in the EU without a VAT number are subject to 21% VAT Belgian Government tax. The 21% VAT is not applicable to organisations outside of the EU.
**Corporate subscriptions receive five (5) copies of the journal.
Back issues, PDF licences and reprints are available for purchase. Contact us for more details.
GaBI Journal – print ISSN: 2033-6403; online ISSN: 2033-6772
Bulk subscriptions
Contact us for all requests from industry, agencies, and companies regarding bulk subscriptions.
Change of address notice
Both subscriber’s old and new addresses should be sent to us via email at least six weeks in advance.
Claims
When claims for undelivered or damaged issues are made within four months of publication of the issue, a complimentary replacement issue will be provided.
Pingback: Guest Blog: GaBI – Building trust in cost-effective treatments - Total Biopharma : Total Biopharma